ArticleBiosafety and health2026
Seroepidemiological study of pertussis in Henan Province, China, and prediction of the effectiveness of a new immunization strategy.
Article in Biosafety and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study objectives were to analyze the epidemiological characteristics of pertussis in Henan Province, China, and to evaluate the impact of pertussis vaccination strategy adjustments on population infection rates. A retrospective analysis was conducted on the reported pertussis cases in Henan Province from 2012 to 2024. The concentration of IgG antibodies against pertussis toxin (anti-PT IgG) was measured in 18,528 healthy individuals from 2022 to 2024. The positive rate (≥20 IU/mL) and median concentration (MC) were calculated, and the infection rate was estimated based on anti-PT IgG ≥ 40 IU/mL, using the susceptible-exposed-infectious-recovered-vaccinated (SEIRV) model to predict the effect of adding a pertussis booster dose at 6 years. The average annual incidence of pertussis in Henan Province from 2012 to 2024 was 2.21 per 100,000 population. The overall anti-PT IgG positivity rate was 16.42 %, and the MC was 4.66 IU/mL. The antibody concentration is influenced by age, gender, and vaccine type. The population that completed the full course of vaccination had the highest anti-PT IgG positive rate (17.81 %) and the highest MC (4.97 IU/mL). The population that vaccinated the diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-haemophilus influenzae type b (DTaP-IPV/ Hib) had the highest MC (14.83 IU/mL). The total estimated infection rate of pertussis was 7,833.45 per 100,000, peaking in the 6-year age group (10,809.72 per 100,000). When the estimated coverage rate of the pertussis booster vaccination reaches 83.21 %, the infection rate could be decreased by 71.41 %. The incidence of pertussis in Henan Province has increased, and the infection rate is higher than anticipated. Booster immunization at age six can significantly lower the risk of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.